Publications

Optimizing APL management using big data (PI: Maria Teresa Voso) Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell N, Dillon R, Thomas I, Ossenkoppele G, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Ramiro AV, Giménez LT, Gurnari C, Bullinger L, Hernández-Rivas JM. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood 2025; 145(2): 234-243.

Outcomes with intensive treatment for acute myeloid leukemia over two decades: An analysis from the HARMONY Alliance (PI: M. Sobas) Sobas MA, Turki AT, Ramiro AV, Sánchez AH, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall’Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Haematologica. 2025 May 1;110(5):1126-1140. doi: 10.3324/haematol.2024.285805.

Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia (PI: R. Mecklenbrauck). Mecklenbrauck R, Borchert N, Gabdoulline R, Poll P, Funke C, Brandes M, Dallmann LK, Fiedler W, Krauter J, Trummer A, Hertenstein B, Müller M, Lübbert M, Schwalenberg M, Voss A, Di Donato N, Bergmann A, Gaidzik V, Döhner K, Döhner H, Ganser A, Heidel FH, Thol FR, Heuser M. Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia. Leukemia. 2025 Jul;39(7):1773-1777. doi: 10.1038/s41375-025-02622-6. Measurable residual disease as a surrogate marker for survival in AML (PI: Gert Ossenkoppele). Oral presentation, Annual Meeting of the American Society of Hematology, Blood (2025) 146 (Supplement 1):343

Independent, international validation of the HARMONY unsupervised genomic AML classification (PI: Armin Turki) Oral presentation, Annual Meeting of the American Society of Hematology, Blood (2025) 146 (Supplement 1):451

EHA AML-Specialized Working Group Project (PI: C. Gunari) Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG) Oral presentation, Annual Meeting of the American Society of Hematology, Blood (2025) 146 (Supplement 1):217

Precision hematology: Navigating the evolution of diagnostic classifications in the era of globalized medicine
Macintyre E, Döhner K, Grønbæk K, Dreyling M, Huntly B, Almeida A, Gribben J; EHA Board
Hemasphere. 2024 Apr 4;8(4):e65.

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study
Alberto Hernández-Sánchez, Teresa González, Marta Sobas, Eric Sträng, Gastone Castellani, María Abáigar, Peter J M Valk, Ángela Villaverde Ramiro, Axel Benner, Klaus H Metzeler, Raúl Azibeiro, Jesse M Tettero, Joaquín Martínez-López, Marta Pratcorona, Javier Martínez Elicegui, Ken I Mills, Christian Thiede, Guillermo Sanz, Konstanze Döhner, Michael Heuser, Torsten Haferlach, Amin T Turki, Dirk Reinhardt, Renate Schulze-Rath, Martje Barbus, Jesús María Hernández-Rivas, Brian Huntly, Gert Ossenkoppele, Hartmut Döhner, Lars Bullinger.
Leukemia 2024 Sep;38(9):1929-1937.

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
Sobas MA, Turki AT, Ramiro AV, Hernández-Sánchez A, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall’Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L.
Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.285805. Online ahead of print.

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell N, Dillon R, Thomas I, Ossenkoppele G, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Ramiro AV, Giménez LT, Gurnari C, Bullinger L, Hernández-Rivas JM.
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood. 2025 Jan 9;145(2):234-243.
Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Wei AH, Löwenberg B.
Blood. 2024 Nov 21;144(21):2169-2173.

Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities
Lubbers BR, Dombrink I, Kalina T, Hofmans M, Bruun MS, Stanworth SJ, Béné MC, Döhner K, Brüggemann M, Macintyre E, van Dongen JJM.
Hemasphere. 2023;7(5):e877.

A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care
El-Galaly TC, Gaidzik VI, Gaman MA, Antic D, Okosun J, Copland M, Sexl V, Fielding AK, Doeswijk R, Parker H, Dreyling M, Döhner K, Almeida AM, Macintyre E, Gribben JG, Grønbæk K.
Hemasphere. 2023;7(3):e842.

Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
Ravandi F, Cloos J, Buccisano F, Dillon R, Döhner K, Freeman SD, Hourigan CS, Ossenkoppele GJ, Roboz GJ, Subklewe M, Thiede C, Arnhardt I, Valk PJM, Venditti A, Wei AH, Walter RB, Heuser M.
Am J Hematol. 2023;98(12):1847-1855.